| Mrs Sitamahalakshmi Yerramalli, MD | |
|
1 Clara Maass Dr Ste 200, Belleville, NJ 07109-3550 | |
| (973) 751-8880 | |
| (973) 751-8950 |
| Full Name | Mrs Sitamahalakshmi Yerramalli |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 47 Years |
| Location | 1 Clara Maass Dr Ste 200, Belleville, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780676759 | NPI | - | NPPES |
| 0154709 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 25MA03850700 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New Jersey Cancer Care, Pa | 3971603788 | 10 |
News Archive
"India will not compromise on drug licensing norms and [will] continue to produce generic drugs for free treatment to HIV-positive patients, Commerce and Industry Minister Anand Sharma said" on Wednesday, the IANS/Times of India reports.
Two new studies on Hepatitis C (HCV) patients who underwent liver transplants examined a potential biomarker that could be used to predict who might develop hepatic fibrosis, a formation of scar-like tissue that can lead to cirrhosis.
Exposure to particulate matter has been recognized as a contributing factor to lung cancer development for some time, but a new study indicates inhalation of certain particulates can actually cause some genes to become reprogrammed, affecting both the development and the outcome of cancers and other diseases.
The Pittsburgh Protocol is unique in utilizing bone marrow cells to enable reduction of the need for multiple anti-rejection drugs after transplantation. The University of Pittsburgh Medical Center is currently the only transplantation center in the world to offer it. An early report of the initial experience with the "Pittsburgh Protocol" in three recipients of upper extremity transplants was presented during the 2010 Annual Clinical Congress of the American College of Surgeons.
BG Medicine, Inc. today announced that it has entered into a research collaboration with Merck, through a subsidiary, for the development and validation of a novel biomarker with potential application in the management of lipid disorders. BG Medicine will pursue development and validation of an immunoassay and investigate its clinical utility as a biomarker. If successful, BG Medicine plans to complete the development and validation studies and seek regulatory clearance for the test.
› Verified 5 days ago
| Entity Name | New Jersey Cancer Care, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447315502 PECOS PAC ID: 3971603788 Enrollment ID: O20070710000160 |
News Archive
"India will not compromise on drug licensing norms and [will] continue to produce generic drugs for free treatment to HIV-positive patients, Commerce and Industry Minister Anand Sharma said" on Wednesday, the IANS/Times of India reports.
Two new studies on Hepatitis C (HCV) patients who underwent liver transplants examined a potential biomarker that could be used to predict who might develop hepatic fibrosis, a formation of scar-like tissue that can lead to cirrhosis.
Exposure to particulate matter has been recognized as a contributing factor to lung cancer development for some time, but a new study indicates inhalation of certain particulates can actually cause some genes to become reprogrammed, affecting both the development and the outcome of cancers and other diseases.
The Pittsburgh Protocol is unique in utilizing bone marrow cells to enable reduction of the need for multiple anti-rejection drugs after transplantation. The University of Pittsburgh Medical Center is currently the only transplantation center in the world to offer it. An early report of the initial experience with the "Pittsburgh Protocol" in three recipients of upper extremity transplants was presented during the 2010 Annual Clinical Congress of the American College of Surgeons.
BG Medicine, Inc. today announced that it has entered into a research collaboration with Merck, through a subsidiary, for the development and validation of a novel biomarker with potential application in the management of lipid disorders. BG Medicine will pursue development and validation of an immunoassay and investigate its clinical utility as a biomarker. If successful, BG Medicine plans to complete the development and validation studies and seek regulatory clearance for the test.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Sitamahalakshmi Yerramalli, MD 1 Clara Maass Dr Ste 200, Belleville, NJ 07109-3550 Ph: (973) 751-8880 | Mrs Sitamahalakshmi Yerramalli, MD 1 Clara Maass Dr Ste 200, Belleville, NJ 07109-3550 Ph: (973) 751-8880 |
News Archive
"India will not compromise on drug licensing norms and [will] continue to produce generic drugs for free treatment to HIV-positive patients, Commerce and Industry Minister Anand Sharma said" on Wednesday, the IANS/Times of India reports.
Two new studies on Hepatitis C (HCV) patients who underwent liver transplants examined a potential biomarker that could be used to predict who might develop hepatic fibrosis, a formation of scar-like tissue that can lead to cirrhosis.
Exposure to particulate matter has been recognized as a contributing factor to lung cancer development for some time, but a new study indicates inhalation of certain particulates can actually cause some genes to become reprogrammed, affecting both the development and the outcome of cancers and other diseases.
The Pittsburgh Protocol is unique in utilizing bone marrow cells to enable reduction of the need for multiple anti-rejection drugs after transplantation. The University of Pittsburgh Medical Center is currently the only transplantation center in the world to offer it. An early report of the initial experience with the "Pittsburgh Protocol" in three recipients of upper extremity transplants was presented during the 2010 Annual Clinical Congress of the American College of Surgeons.
BG Medicine, Inc. today announced that it has entered into a research collaboration with Merck, through a subsidiary, for the development and validation of a novel biomarker with potential application in the management of lipid disorders. BG Medicine will pursue development and validation of an immunoassay and investigate its clinical utility as a biomarker. If successful, BG Medicine plans to complete the development and validation studies and seek regulatory clearance for the test.
› Verified 5 days ago
Dr. Etan B Spira, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5 Franklin Ave, Suite 109, Belleville, NJ 07109 Phone: 973-759-7240 Fax: 973-759-7243 | |
Dr. Jimmy Martins Paulo, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Clara Maass Dr Ste 202, Belleville, NJ 07109 Phone: 973-450-2433 Fax: 973-450-2434 | |
Hemalatha Vasireddy, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Clara Maass Dr Ste 200, Belleville, NJ 07109 Phone: 973-751-8880 Fax: 973-751-8950 | |
Dr. Mario A Criscito, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 50 Newark Ave, Suite 204, Belleville, NJ 07109 Phone: 973-450-2158 Fax: 973-450-2027 | |
John Daconti, DO Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 77 Newark Ave, Suite 3 & 4, Belleville, NJ 07109 Phone: 973-528-2160 Fax: 973-528-2165 | |
Jaxon James Fernandes, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1 Clara Maass Dr, Belleville, NJ 07109 Phone: 973-450-2000 | |
Dr. Dianne Walker, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 303 Belmont Ave, Belleville, NJ 07109 Phone: 973-751-4818 Fax: 973-751-4886 |